Zhaomei Mu
Overview
Explore the profile of Zhaomei Mu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
908
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mu Z, Benali-Furet N, Uzan G, Znaty A, Ye Z, Paolillo C, et al.
Int J Mol Sci
. 2016 Oct;
17(10).
PMID: 27706044
The availability of blood-based diagnostic testing using a non-invasive technique holds promise for real-time monitoring of disease progression and treatment selection. Circulating tumor cells (CTCs) have been used as a...
12.
Udayakumar T, Stoyanova R, Shareef M, Mu Z, Philip S, Burnstein K, et al.
Mol Cancer Ther
. 2016 Mar;
15(6):1353-63.
PMID: 26944919
Edelfosine is a synthetic alkyl-lysophospholipid that possesses significant antitumor activity in several human tumor models. Here, we investigated the effects of edelfosine combined with androgen deprivation (AD) in LNCaP and...
13.
Mizue Terai , Mu Z, Eschelman D, Gonsalves C, Kageyama K, Chervoneva I, et al.
EBioMedicine
. 2016 Feb;
2(11):1821-6.
PMID: 26870807
Background: CTCs provide prognostic information and their application is under investigation in multiple tumor types. Of the multiple variables inherent in any such process, none is more important to outcome...
14.
Mu Z, Wang C, Ye Z, Austin L, Civan J, Hyslop T, et al.
Breast Cancer Res Treat
. 2015 Nov;
154(3):563-71.
PMID: 26573830
The enumeration of circulating tumor cells (CTCs) provides important prognostic values in patients with metastatic breast cancer. Recent studies indicate that individual CTCs form clusters and these CTC-clusters play an...
15.
Lai Y, Ye Z, Civan J, Wang C, Cristofanilli M, Mu Z, et al.
Breast Cancer Res Treat
. 2015 Aug;
153(2):407-16.
PMID: 26264468
Current clinical guidelines state that the use of erythropoiesis-stimulating agents (ESAs) may be considered to treat chemotherapy-induced anemia in the non-curative setting to alleviate anemia-related symptoms. However, no convincing survival...
16.
Toss A, Mu Z, Fernandez S, Cristofanilli M
Ann Transl Med
. 2014 Dec;
2(11):108.
PMID: 25489582
The primary cause of tumor-related death in breast cancer (BC) is still represented by distant metastasization. The dissemination of tumor cells from the primary tumor to distant sites through bloodstream...
17.
Mu Z, Klinowska T, Dong X, Foster E, Womack C, Fernandez S, et al.
J Exp Clin Cancer Res
. 2014 Jun;
33:47.
PMID: 24886365
Introduction: Epidermal growth factor receptor (EGFR) overexpression has been associated with prognostic and predictive value in inflammatory breast cancer (IBC). Epidermal growth factor receptor 2 (HER2) overexpression is observed at...
18.
Mu Z, Li H, Fernandez S, Alpaugh K, Zhang R, Cristofanilli M
J Exp Clin Cancer Res
. 2013 Dec;
32:70.
PMID: 24294976
Introduction: Inflammatory breast cancer (IBC) is the most metastatic variant of breast cancer with the poorest survival in all types of breast cancer patients and presently therapeutic targets for IBC...
19.
Robertson F, Petricoin Iii E, Van Laere S, Bertucci F, Chu K, Fernandez S, et al.
Springerplus
. 2013 Oct;
2:497.
PMID: 24102046
Although Inflammatory Breast Cancer (IBC) is recognized as the most metastatic variant of locally advanced breast cancer, the molecular basis for the distinct clinical presentation and accelerated program of metastasis...
20.
Fernandez S, Robertson F, Pei J, Aburto-Chumpitaz L, Mu Z, Chu K, et al.
Breast Cancer Res Treat
. 2013 Jun;
140(1):23-33.
PMID: 23784380
Inflammatory breast cancer (IBC) is the most aggressive type of advanced breast cancer characterized by rapid proliferation, early metastatic development and poor prognosis. Since there are few preclinical models of...